Filtered By:
Specialty: Neurology
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 551 results found since Jan 2013.

Stroke-unit care for stroke patients in China: the results from Bigdata Observatory platform for Stroke of China
ConclusionsAmong patients with stroke, admission to a designated SU was associated with modestly lower mortality at discharge, reduced probability of death, or being disabled at the end of follow-up.
Source: Journal of Neurology - April 22, 2021 Category: Neurology Source Type: research

Hyperdense middle cerebral artery sign in large cerebral infarction
ConclusionsHMCAS in patients with a large cerebral infarction without thrombolytic therapy is an independent biomarker of HT. Length of HMCAS is also a marker of HT with lower ASPECTS in HMCAS patients.
Source: Brain and Behavior - March 25, 2021 Category: Neurology Authors: Jie Hou, Yu Sun, Yang Duan, Libo Zhang, Dengxiang Xing, Xiaoqiu Lee, Benqiang Yang Tags: ORIGINAL RESEARCH Source Type: research

Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma
In conclusion, we identified single nucleotide variants in theZBTB46 gene associated with a higher risk of parenchymal haematoma following recombinant tissue-plasminogen activator treatment.
Source: Brain - March 16, 2021 Category: Neurology Source Type: research

Health-related quality of life after ischemic stroke: impact of sociodemographic and clinical factors
CONCLUSION: Stroke survivors have significantly reduced HR-QoL. Multiple interacting factors are associated with an unfavorable outcome after IS. Early detection of these factors would help to improve the care for IS patients, to reduce disabilities and improve HR-QoL.PMID:33637026 | DOI:10.1080/01616412.2021.1893563
Source: Neurological Research - February 27, 2021 Category: Neurology Authors: M Tsalta-Mladenov S Andonova Source Type: research

The Efficacy and Safety of Intravenous Thrombolysis in Older Chinese Patients with Acute Ischemic Stroke
Ming Xu, Jiamei Guo, Xianming Tao, Kebin ZengNeurology India 2021 69(1):91-96 To study the efficacy and safety of intravenous thrombolysis for the older acute ischemic stroke patients, clinical data were prospectively analyzed from 168 patients with acute ischemic stroke including 42 older adult patients (ET group), 66 younger patients (NET group) treated with rt-PA, and 60 older adult patients treated without rt-PA (ENT group). Stroke severity was assessed with an NIHSS score at baseline, 1-day and 14-day after treatment. Functional outcomes were evaluated by the modified Rankin scale and a Barthel index. Adverse effects...
Source: Neurology India - February 24, 2021 Category: Neurology Authors: Ming Xu Jiamei Guo Xianming Tao Kebin Zeng Source Type: research

Is Endovascular Therapy for Stroke Cost-Effective Globally? A Systematic Review of the Literature
The standard of care for eligible patients with acute ischemic stroke (AIS) has been thrombolytic therapy with intravenous (IV) tissue plasminogen activator (tPA) within 4.5  h of symptom onset to achieve reperfusion and reduce morbidity and mortality.1-3 However, the emergence of endovascular therapy (EVT) has changed the treatment paradigm for large vessel occlusion (LVO) acute ischemic stroke (AIS). The evidence supporting the use of EVT as first-line treatment for LVO stroke is unequivocal.45
Source: Journal of Stroke and Cerebrovascular Diseases - February 5, 2021 Category: Neurology Authors: Muhammad Waqas, Andrew D. Gong, Bennett R. Levy, Rimal H. Dossani, Kunal Vakharia, Justin M. Cappuzzo, Alexander Becker, Ashish Sonig, Vincent M. Tutino, Faisal Almayman, Jason M. Davies, Kenneth V. Snyder, Adnan H. Siddiqui, Elad I. Levy Source Type: research

Reply to: Response to “measuring the optic nerve sheath diameter with ultrasound in acute middle cerebral artery stroke patients”: For application to Long-Duration Spaceflight (LDSF)
We thank Mohanadass and Church for their interest in using Optic Nerve Sheath Diameter (ONSD) measurements in Acute Middle Cerebral Artery (MCA) stroke patients to evaluate the effect of thrombolytic therapy and identify high-risk patients.1
Source: Journal of Stroke and Cerebrovascular Diseases - January 23, 2021 Category: Neurology Authors: Seda G üzeldağ, Gökhan Yılmaz Tags: Letter to the Editor Source Type: research

Response to “Measuring the Optic Nerve Sheath Diameter with Ultrasound in Acute Middle Cerebral Artery Stroke Patients”: For Application to Long-Duration Spaceflight (LDSF)
We thank the authors of the study for their contribution to literature and their insights into the utilisation of optic nerve sheath diameter (ONSD) measurements with regards to therapeutic efficacy of thrombolytic therapy (TT) and identification of complications in populations post-MCA stroke. We would like to introduce the discussion of potential translational benefits of this methodology to the field of long-duration spaceflight (LDSF).
Source: Journal of Stroke and Cerebrovascular Diseases - January 20, 2021 Category: Neurology Authors: Chloe A. Mohanadass, Lauren E. Church Tags: Letter to the Editor Source Type: research

Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research

Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis
The efficacy of thrombolytic therapy with tissue plasminogen activator (tPA) is highly time dependent. Although clinical guidelines do not recommend written informed consent as it may cause treatment delays, local policy can supersede and require it. From 2014 to 2017, three out of five public hospitals in Singapore changed from written to verbal consent at different time points. We aimed to examine the association of hospital policy changes regarding informed consent on door-to-needle (DTN) times.
Source: Journal of Stroke and Cerebrovascular Diseases - December 19, 2020 Category: Neurology Authors: Hanzhang Xu, Deidre Anne De Silva, Fung Peng Woon, Marcus Eng Hock Ong, David B. Matchar, Janet Prvu Bettger, Daniel T. Laskowitz, Ying Xian Source Type: research

Knowledge of Acute Stroke Management Among Healthcare Professionals: Development and Validation of Acute Stroke Management Questionnaire (ASMaQ)
Around 15.0% of all strokes occurred in hospitalised patients and studies showed significant delay in the stroke recognition and lack of awareness on thrombolytic therapy for acute ischaemic stroke (AIS) which lead to higher mortality for in-hospital stroke. We aimed to develop and validate a new instrument known as acute stroke management questionnaire (ASMaQ) to evaluate the awareness of healthcare professionals in managing acute ischaemic stroke cases.
Source: Journal of Stroke and Cerebrovascular Diseases - November 4, 2020 Category: Neurology Authors: Chun yang Sim, Wan Asyraf Wan Zaidi, Shamsul Azhar Shah, Wan Nur Nafisah Wan Yahya, Hui jan Tan Source Type: research